Skip to content

Palvella Therapeutics, Inc.: 10-Q filed 2017-11-13

What Palvella Therapeutics, Inc. reported in its quarterly report filed 2017-11-13 (fiscal Q3 2017): 30 published measures, 79 facts as tagged in accession 0001193125-17-339158.

This filing

Form
10-Q (quarterly report)
Filed
2017-11-13
Fiscal period
fiscal Q3 2017
Accession
0001193125-17-339158 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Palvella Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2017-09-3098,861,143USD
At 2016-12-3135,062,831USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2017-09-3094,302,930USD
At 2016-12-319,836,304USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2017-09-304,558,213USD
At 2016-12-3125,226,527USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2017-09-3089,921,213USD
At 2016-12-3129,355,528USD
At 2016-09-3036,557,701USD
At 2015-12-3129,349,124USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2017-07-01 to 2017-09-30-7,058,824USD92
2017-01-01 to 2017-09-30-25,137,425USD273
2016-07-01 to 2016-09-30-6,196,203USD92
2016-01-01 to 2016-09-30-16,240,511USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2017-01-01 to 2017-09-301,141,727USD273
2016-01-01 to 2016-09-30322,706USD274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2017-07-01 to 2017-09-303,927,204USD92
2017-01-01 to 2017-09-307,123,362USD273
2016-07-01 to 2016-09-30785,007USD92
2016-01-01 to 2016-09-303,104,513USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2017-09-30-127,802,279USD
At 2016-12-31-102,664,853USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2017-07-01 to 2017-09-30145,697USD92
2017-01-01 to 2017-09-30959,406USD273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2017-09-303,455,541USD
At 2016-12-312,264,477USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2017-01-01 to 2017-09-301,962,018USD273
2016-01-01 to 2016-09-301,426,341USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2017-07-01 to 2017-09-30-5,184,411USD92
2017-01-01 to 2017-09-30-21,081,392USD273
2016-07-01 to 2016-09-30-6,177,960USD92
2016-01-01 to 2016-09-30-16,354,086USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2017-09-3095,276,331USD
At 2016-12-3132,672,613USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2017-09-3039,037,882USD
At 2016-12-318,380,154USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2017-09-302,601,736USD
At 2016-12-312,386,183USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2017-09-302,537,265USD
At 2016-12-3157,582USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2017-07-01 to 2017-09-309,111,615USD92
2017-01-01 to 2017-09-3028,204,754USD273
2016-07-01 to 2016-09-306,962,967USD92
2016-01-01 to 2016-09-3019,458,599USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2017-07-01 to 2017-09-306,259,258USD92
2017-01-01 to 2017-09-3017,014,938USD273
2016-07-01 to 2016-09-304,621,957USD92
2016-01-01 to 2016-09-3012,781,489USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2017-09-3044,704,849shares
At 2016-12-3143,058,827shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2017-09-30-2,487,336USD
At 2016-12-31-1,501,452USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2017-09-30129,271USD
At 2016-12-31125,741USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2017-09-3043,462USD
At 2016-12-3146,667USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2017-09-305,099,918USD
At 2016-12-313,719,457USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2017-09-302,817,853USD
At 2016-12-313,259,503USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2017-07-01 to 2017-09-30-6,913,127USD92
2017-01-01 to 2017-09-30-24,178,019USD273
2016-07-01 to 2016-09-30-6,196,203USD92
2016-01-01 to 2016-09-30-16,240,511USD274

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2017-07-01 to 2017-09-30-7,453,638USD92
2017-01-01 to 2017-09-30-26,123,310USD273
2016-07-01 to 2016-09-30-6,195,533USD92
2016-01-01 to 2016-09-30-16,293,041USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2017-07-01 to 2017-09-302,852,357USD92
2017-01-01 to 2017-09-3011,189,816USD273
2016-07-01 to 2016-09-302,341,010USD92
2016-01-01 to 2016-09-306,677,110USD274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2017-01-01 to 2017-09-30268,213USD273
2016-01-01 to 2016-09-30175,387USD274

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2017-07-01 to 2017-09-30-1,728,812USD92
2017-01-01 to 2017-09-30-3,096,890USD273
2016-07-01 to 2016-09-30-18,243USD92
2016-01-01 to 2016-09-30113,575USD274

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2017-01-01 to 2017-09-302,336,887USD273

Inspect the source

Entity
Palvella Therapeutics, Inc. / CIK 0001583648
Captured
2026-09-20T09:22:58.497Z
SEC response SHA-256
6b68c40c9037b15f9345bb6bb1fdc7777b1252c77cab2e34faa81275beefef40

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001583648.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))